Robert Cobuzzi, Diffusion Pharmaceuticals president and CEO
In bid to keep itself afloat, tiny Diffusion Pharmaceuticals mulls out-licensing core tech or company sale
A Virginia biotech is now looking at all its options to keep itself going, even if that means selling core company technology or even the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
